You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Second remission

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

Recruiting
  • Multiple Myeloma in Remission
  • MM-specific universal CAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Aug 23, 2023

Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in New York (NY-ESO-1 OLP4, NY-ESO-1 OLP4 +

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +2 more
  • NY-ESO-1 OLP4
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Bipolar Affective Disorder Trial in Moscow (Quetiapine)

Recruiting
  • Bipolar Affective Disorder
  • Moscow, Russian Federation
    Mental health research center
Oct 18, 2021

MAFLD in Type 2 Diabetes in Jiangsu Province of China

Recruiting
  • Type 2 Diabetes Mellitus in Remission
  • Metabolic Associated Fatty Liver Disease
  • Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
  • Nanjing, Jiangsu, China
    Zhongda Hospital, Medical School, Southeast University
Oct 24, 2022

Platelet Transfusion Refractoriness, Acute Leukemia in Remission Trial in Suzhou (CAR-T infusion)

Recruiting
  • Platelet Transfusion Refractoriness
  • Acute Leukemia in Remission
  • CAR-T infusion
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 19, 2021

MDD, Remission Trial in Shanghai (treatment as usual)

Recruiting
  • Major Depressive Disorder
  • Remission
  • treatment as usual
  • Shanghai, China
    Shanghai Mental Health Center
Jul 22, 2021

Autoimmune Diseases Trial in Hangzhou (Standard dose of rituximab, Individualized dose of rituximab)

Recruiting
  • Autoimmune Diseases
  • Standard dose of rituximab
  • Individualized dose of rituximab
  • Hangzhou, Zhejiang, China
    Second affiliated hospital of zhejiang university，school of medi
Nov 15, 2020

Primacy Immune Thrombocytopenia Trial in Italy (Eltrombopag)

Completed
  • Primacy Immune Thrombocytopenia
  • Bologna, Italy
  • +13 more
Aug 13, 2021

Multiple Myeloma Trial in Little Rock (myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC

Terminated
Has Results
  • Multiple Myeloma
  • myPRS
  • +6 more
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
May 28, 2021

Childhood Acute Lymphoblastic Leukemia Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD 19+22)

Recruiting
  • Childhood Acute Lymphoblastic Leukemia
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

Relapsed or Refractory Multiple Myeloma Trial in Shijiazhuang (BCMA CAR-T, Fludarabine, Cyclophosphamide)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • BCMA CAR-T
  • +2 more
  • Shijiazhuang, Hebei, China
    the Second Hospital of HeBei Medical University (HBMU)
Nov 11, 2020

Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia Trial in Beijing (donor lymphocyte

Unknown status
  • Donor Lymphocyte Infusion
  • +5 more
  • donor lymphocyte infusion
  • Beijing, Beijing, China
    Peking University Institute of Hematology,Beijing
Mar 9, 2020

Neuroblastoma Trial in New York (3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid)

Terminated
Has Results
  • Neuroblastoma
  • 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Nov 12, 2019

Hodgkin Lymphoma, Adult Trial in Spain (Induction with Brentuximab vedotin (BV), Induction without Brentuximab Vedotin,

Recruiting
  • Hodgkin Lymphoma, Adult
  • Induction with Brentuximab vedotin (BV)
  • +2 more
  • Oviedo, Asturias, Spain
  • +18 more
Nov 28, 2020

Breast Cancer Trial in Changchun, Shenyang (complete remission (CR) group, partial remission (PR) group, stable disease (SD)

Completed
  • Breast Cancer
  • complete remission (CR) group
  • +3 more
  • Changchun, Jilin, China
  • +2 more
Feb 19, 2020

Acute Myeloid Leukemia Trial in Scottsdale, Houston (Galinpepimut-S, Best Available Therapy)

Unknown status
  • Acute Myeloid Leukemia
  • Galinpepimut-S
  • Best Available Therapy
  • Scottsdale, Arizona
  • +1 more
Feb 14, 2020

DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)

Recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Mar 27, 2023

Crohn Disease Trial in Baltimore, New York (Ustekinumab)

Recruiting
  • Crohn Disease
  • Baltimore, Maryland
  • +1 more
Jul 29, 2022

CDED in a Real World IBD Clinic

Recruiting
  • Crohn Disease
    • Tel Aviv, Israel
    • +1 more
    Oct 11, 2022

    AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

    Recruiting
    • AML
    • MDS
    • Tuebingen, Baden-Wuerttemberg, Germany
      University Hospital
    Nov 30, 2023

    CD Trial in Leuven, Clichy (Colonoscopy)

    Completed
    • CD
    • Colonoscopy
    • Leuven, Belgium
    • +1 more
    Aug 2, 2022

    Acute Leukemia of Ambiguous Lineage Trial in Suzhou (Venetoclax, azactidine)

    Recruiting
    • Acute Leukemia of Ambiguous Lineage
    • Suzhou, China
      The First Affliated Hospital of Soochow University
    Jun 14, 2023

    Secondary Acute Myeloid Leukemia Trial in Ann Arbor (Venetoclax, FLAG Protocol)

    Not yet recruiting
    • Secondary Acute Myeloid Leukemia
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Mar 22, 2023

    Functional Remission in Discharged Schizophrenia After Long-term

    Recruiting
    • Schizophrenia
      • Shanghai, Shanghai, China
        Shanghai Mental Health Center, Shanghai Jiao Tong University Sch
      Dec 28, 2022

      Giant Cell Arteritis Trial in Bonn (Methotrexate, Sodium chloride)

      Recruiting
      • Giant Cell Arteritis
      • Bonn, Germany
        Medical Clinic and Polyclinic III Internal medicine Oncology, He
      Dec 16, 2022